New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01E and BCG-revaccinationFriday, August 9, 2024Availability, Economic impact/cost-effectivenss, Epidemiological impactRead More
An investment case for new tuberculosis vaccinesFriday, August 9, 2024Availability, Policy and frameworksRead More
WHO evidence considerations for vaccine policy development for tuberculosis vaccines intended for adults and adolescentsFriday, August 9, 2024Availability, Policy and frameworksRead More
WHO preferred product characteristics for new tuberculosis vaccineFriday, August 9, 2024Availability, Policy and frameworksRead More
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling studyFriday, August 9, 2024Availability, Epidemiological impactRead More
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling studyFriday, August 9, 2024Availability, Economic impact/cost-effectivenssRead More
The Health and Economic Benefits Possible with Novel Tuberculosis Vaccines – A Modeling Study in India and Indonesia.Tuesday, July 16, 2024Available, demand assessedRead More
Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India.Tuesday, July 16, 2024Available, demand assessedRead More
